Philippe Aftimos, MD
@aftimosp.bsky.social
Breast oncologist and clinical researcher 🩺🔬at Institut Jules bordet 🏥. Dad of a 5-yo 🧑🧒 and of a cat 🐈. Nature lover 🌳, oud enthusiast 🎼, vegan 🌱, RUSG fan ⚽️💛💙. Proud citizen of Wokistan.
With #ESMO26 in Madrid around the corner, the LBAs list os now available online and in the program! #ESMOAmbassadors
ESMO - European Society for Medical Oncology@myesmo.bsky.social · last mo.📣 #ESMO26: The late-breaking abstract lineup is taking shape! Authors & titles are online, and most of the submissions are already there. 30K+ delegates already registered from around the world, so this means new data, new insights and new opportunities to connect. 🔗 https://ow.ly/6Res50ZQ82a
I am thrilled to be part of this group with stellar ⭐️ colleagues and I look forward to interactions and discussions around high quality data at #ESMO26 ! #ESMOAmbassadors
ESMO - European Society for Medical Oncology@myesmo.bsky.social · last mo.ESMO is pleased to announce the #ESMOAmbassadors for #ESMO26. They will share scientific highlights, expert perspectives and insights on the latest research presented at #ESMO26 across tumour types and disciplines. 🔗Discover the Ambassadors: https://ow.ly/BQ3i50ZOkEv
In #RareCancers, guidelines are vital to bring together scattered expertise. A recent EURACAN survey highlights a high uptake of recommendations from oncologists, potentially leading to improved patients’ survival. #ESMORareCancers26 #ESMODailyReporter 📌 https://ow.ly/nooJ50YsIQ9
Do you have an impactful research idea? One that could improve care or advance science? Apply for the ESMO Leadership & Career Development Award, offering protected research time, leadership & communication training by 3 May 26 . 🔗https://ow.ly/Gicm50YqcbZ #Oncology #ESMOYOC
Spiderweb 🕸️ is a decentralised clinical trials initiative by the Oncodistinct network. Learn more in this commentary by Nuria Kotecki and Simon Nannini ascopubs.org/doi/10.1200/...
Innovative Research Organization to Facilitate Clinical Trials Implementation in the Era of Molecular Oncology: The Spiderweb Model of the Oncodistinct Network | JCO Precision Oncology
ascopubs.org
January 16 & 17, 2026 - Brussels Two days packed with top expertise, debate, and insights from the past year in breast cancer care. Institut Jules Bordet & UZ Leuven invite you to this annual double meeting, which has become a fixture Registration link ✍️👇 accredimix.be/debate-highl...
Rotterdam citytrip and Union Saint-Gilloise 💛💙 at De Kuip 🚂☀️🚤🏟️
I am a big fan of @fontainesdc.bsky.social and I discovered their partnership with @bfcdublin.bsky.social at Rock Werchter. I immediately loved the club’s vibes. And that third jersey, wow 🤩
I reviewed for @myesmo.bsky.social new data with a potential clinical impact in HR+/HER2- metastatic breast cancer 👇
ESMO - European Society for Medical Oncology@myesmo.bsky.social · last yr.Novel evidence demonstrates the clinical utility of circulating tumour DNA in patients with HR+/HER2- cancers harbouring ESR1 and PIK3CA mutations. Read the opinion by @aftimosp.bsky.social in the #ESMODailyReporter 🔗 buff.ly/QGEixeU #MBC #BreastCancer #ctDNA
#ESMOMembers – vote for the leaders who will shape ESMO’s future. Vote now for the Directors of Education, Public Policy & Membership - and the Chair and members of the Nomination Committee. 📽️ Watch the ESMO President’s message 🔗 Vote now: ow.ly/H7UK50VZR0X
Cool simultaneous illustration of my talk at the seminar series organised by Institut Jules Bordet to celebrate Clinical Trials Day
@hoperugo.bsky.social is discussing the results of the ROSALINE trial, an IIT sponsored by the Institut Jules Bordet that evaluated ROS1 inhibition with neo-adj endocrine therapy in early ILBC #ESMOBreast25 👏🏻 @aftimosp.bsky.social & Soraia Lobo-Martins
Day 2 of #ESMOBreast25 in Munich. Data on ADCs will be presented during Mini Oral session 1 including results on 2️⃣ novel ADCs targeting B7H4 in HR+/HER2- and TNBC: emiltatug ledadotin and puxitatug samrotecan #ESMOAmbassadors @myesmo.bsky.social
In her Keynote Lecture at #ESMOBreast25, @loisher.bsky.social considers the question of who truly benefits from #immunotherapy in #BreastCancer, noting that success hinges on careful definition of responsive patient subgroups. Full article in the #ESMODailyReporter 🔗 ow.ly/rtbo50VSyiN
#ESMOBreast25 Award recipient, Gabriel Hortobagyi, describes the long journey that has led to targeted #BreastCancer therapies and explains how patient involvement is central to advancing research. Read more in the #ESMODailyReporter 🔗 ow.ly/kqju50VSpOE
At #ESMOBreast25, refinements in #LiquidBiopsy use are reviewed, including a defined window for ESR1 mutation detection in metastatic #BreastCancer and use of pre-neoadjuvant treatment #ctDNA levels to predict recurrence. More in the #ESMODailyReporter 🔗 ow.ly/R93050VSChg
An enthusiast and militant talk by @marleenkok.bsky.social at #ESMOBreast25 on the importance of studying biomarkers for immunotherapy in breast cancer, highlighting the KN522 example #ESMOAmbassadors @myesmo.bsky.social
#ESMOBreast25 @laubdh.bsky.social from Institut Jules Bordet on the role of immunotherapy in ER+/HER2- early breast cancer #ESMOAmbassadors @myesmo.bsky.social
#ESMOBreast25: Do not miss the latest research findings in #BreastCancer brought to you by the #ESMOAmbassadors & become part of the conversation. #bcsm 🔗 ow.ly/VtAE50VP4Jf
